1197953-49-3

Basic information

• Product Name: 2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine
• Synonyms: (2-((2,5-dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide;4-(orthodimethylphosphinylanilino)-5-chloro-2-chloropyrimidine;2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine
• CAS NO: 1197953-49-3
• Molecular Formula: C₁₂H₁₂Cl₂N₃OP
• Molecular Weight: 348.121741
• EINECS: 1592732-453-0
• Mol File: 1197953-49-3.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 527.5±50.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.30±0.10(Predicted)
• CAS DataBase Reference: 2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine(1197953-49-3)
• EPA Substance Registry System: 2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine(1197953-49-3)

Safety Data

• Hazardous Substances Data: 1197953-49-3(Hazardous Substances Data)

Usage

General Description

2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine is a synthetic chemical compound used in scientific research and pharmaceutical development. It is a pyrimidine derivative with two chlorine atoms attached to the 2 and 5 positions, and a diMethylphosphoryl group attached to the phenyl ring. 2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine is commonly used as a building block in the synthesis of various pharmaceuticals and bioactive molecules due to its unique structure and reactivity. It is also utilized as a research tool in the study of enzyme inhibitors and bioactive compounds. This chemical compound has potential applications in the development of new drugs for various therapeutic uses, and its precise chemical structure makes it a valuable tool for medicinal chemistry research.

Upstream product

• 161117-84-6 tert-butyl 2-iodophenylcarbamate 
• 5750-76-5 2,4,5-trichloropyrimidine 
• 1197953-47-1 (2-aminophenyl)dimethyl phosphorus oxide 
• 615-43-0 2-iodophenylamine 

Downstream Products

• 1407520-08-4 C₁₈H₂₅ClN₅OP 
• 1407520-42-6 (2-((5-chloro-2-((4-fluoro-2-methoxy-5-nitrophenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide 
• 1407520-52-8 C₂₄H₂₇ClN₅O₆P 
• 1407520-03-9 C₁₉H₂₁ClN₅O₂P 
• 1407519-16-7 N-(3-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)propiolamide 
• 1407519-17-8 C₂₁H₂₃ClN₅O₄PS 
• 1407520-43-7 C₂₆H₃₃ClN₇O₅P 
• 1407520-44-8 C₂₆H₃₅ClN₇O₃P 
• 1407520-49-3 C₂₃H₂₉ClN₇O₄P 
• 1407520-53-9 C₂₂H₂₃ClN₅O₆P 
• 1407520-54-0 C₂₆H₃₂ClN₆O₅P 
• 1407520-55-1 C₂₆H₃₄ClN₆O₄P 
• 1407519-26-9 methyl 2-(((3-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)amino)methyl)acrylate 
• 1407519-27-0 N-(3-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxyphenyl)-2-((dimethylamino)methyl)acrylamide 

Relevant articles and documents

DIMETHYLPHOSPHINE OXIDE COMPOUND

Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.

Preparation method of ALK inhibitor Brigatinib

The invention relates to the technical field of medicines, and relates to a preparation method of a medicine ALK inhibitor AP26113. The method comprises the following steps: (1) carrying out substitution reaction of aromatic amine on 2,4,5-trichloropyrimi

2, 4, 5-substituted pyrimidine compound and preparation method and application thereof

The invention relates to a preparation method of 2, 4-substituted pyrimidine compound and a preparation method and application thereof. The compound has a molecular structure shown as a formula I or pharmaceutically acceptable salt, solvate, stereoisomer or prodrug molecule thereof. The 2, 4, 5-substituted pyrimidine compound is low in cytotoxicity and has high selective inhibition on EGFR; the compound can inhibit the proliferation of EGFR drug-resistant mutant enzymes (such as T790M/L858R/C797S mutant enzymes) and cell strains thereof at a low concentration (such as nanomole concentration),so that the compound can be used for treating diseases caused by EGFR mutation, and is expected to be developed into a new generation of EGFR inhibitors.